<DOC>
	<DOCNO>NCT00005940</DOCNO>
	<brief_summary>This phase II trial study well iodine I 131 monoclonal antibody BC8 , busulfan , cyclophosphamide follow donor stem cell transplant work treat patient acute myeloid leukemia decrease disappeared , cancer may still body . Giving chemotherapy drug , busulfan cyclophosphamide donor peripheral blood stem cell transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . Also , radiolabeled monoclonal antibody , iodine I 131 monoclonal antibody BC8 , find cancer cell carry cancer-killing substance without harm normal cell . When stem cell related donor , closely match patient 's blood , infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet .</brief_summary>
	<brief_title>Radiolabeled BC8 Antibody , Busulfan , Cyclophosphamide Followed Donor Stem Cell Transplant Treating Patients With Acute Myelogenous Leukemia First Remission</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine efficacy ( measure survival disease-free survival ) toxicity regimen busulfan 16 mg/kg cyclophosphamide 120 mg/kg plus 131I-labeled anti-cluster differentiation ( CD ) 45 antibody ( iodine I 131 monoclonal antibody BC8 ) ( deliver dose 5.25 gray [ Gy ] normal organ receive high dose ) patient acute myeloid leukemia ( AML ) first remission receive human leukocyte antigen ( HLA ) -identical related peripheral blood stem cell ( PBSC ) transplant . OUTLINE : RADIOLABELED ANTIBODY : Patients receive iodine I 131 monoclonal antibody BC8 intravenously ( IV ) day -13 . CHEMOTHERAPY : Patients receive busulfan orally ( PO ) every 6 hour day -7 -4 cyclophosphamide IV day -3 -2 . TRANSPLANT : Patients undergo allogeneic PBSC bone marrow ( BM ) transplant day 0 . GRAFT-VS-HOST DISEASE PREVENTION : Patients receive cyclosporine IV PO every 12 hour day -1 50 taper day 180 . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . After completion study treatment , patient follow 6 , 9 , 12 month ; every 6 month 1 year ; yearly thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Patients AML first remission Creatinine &lt; 2.0 mg/dl Bilirubin &lt; 1.5 mg/dl expect exclude patient high risk develop venoocclusive disease liver Aspartate aminotransferase ( AST ) &lt; 1.5 time upper limit normal expect exclude patient high risk develop venoocclusive disease liver Patients must expect survival &gt; 60 day must free major infection DONOR : genotypic phenotypic HLAmatched family member ; relate donor match molecular method intermediate resolution level HLAA , B , C , DR beta 1 ( DRB1 ) accord Fred Hutchinson Cancer Research Center ( FHCRC ) Standard Practice Guidelines allele level DQ beta 1 ( DQB1 ) Patients history current leukemic involvement central nervous system ( CNS ) Prior radiation maximally tolerated level normal organ Inability understand give inform consent Patients seropositive human immunodeficiency virus ( HIV ) Perceived inability tolerate diagnostic therapeutic procedure , particularly treatment radiation isolation Circulating antibody mouse immunoglobulin DONOR : unrelated donor donor mismatch 1 HLA antigen DONOR : donor psychologic , physiologic medical reason unable undergo filgrastim ( GCSF ) mobilize PBSC collection marrow harvest DONOR : donor seropositive HIV</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>